Celltrion Achieves Record-High Second-Quarter Results: Sales KRW 961.5 Billion, Operating Profit KRW 242.5 Billion

Sales and Operating Profit Up by 9.9% and 234.5% Year-on-Year

Celltrion announced on July 21 that its consolidated sales for the second quarter of 2025 reached KRW 961.5 billion, with an operating profit of KRW 242.5 billion, based on preliminary results. Compared to the same period last year, sales increased by 9.9% and operating profit surged by 234.5%. The operating margin also improved to the 25% range. Both sales and operating profit marked record highs for a second quarter.

This performance is attributed to strong sales of existing products in global markets and an expansion in sales centered on new, high-profit products. In particular, the growth of high-margin products such as RemsimaSC (marketed as Zymfentra in the US), Yuflyma, Begzelma, and Stekima has significantly boosted both sales and operating profit. The proportion of sales from new high-margin products rose sharply to 53%, compared to 30% in the same period last year.

The growth trend centered on new products is expected to continue. In the second half of the year, Celltrion is preparing to sequentially launch four new products?Omriclo, Aptozma, Idenzelt, and Stoboclo-Ocenbelt?in major global markets.

The company is also steadily improving profitability through ongoing efforts to reduce costs. In particular, the cost of goods sold ratio, which had temporarily increased due to the merger with Celltrion Healthcare, is rapidly declining. This is due to the depletion of high-cost inventory from before the merger, improvements in production yield, increased utilization of Plant 3 and a reduction in outsourcing of active pharmaceutical ingredient production, and the completion of amortization for development costs of existing products. In the second quarter of this year, the cost ratio was about 43%, a reduction of approximately 15 percentage points from 58% in the same period last year. Compared to the previous quarter, the cost ratio decreased by 4 percentage points in just one quarter, rapidly expanding profitability.

Incheon Songdo Celltrion Plant 2 exterior. Photo by Hyunmin Kim

Celltrion proactively disclosed its preliminary second-quarter results about two weeks earlier than last year in order to promptly inform investors of its growth. However, these are preliminary figures based on internal accounting and may be subject to change after accounting review. The finalized results will be announced separately.

A Celltrion representative stated, "In the second quarter, we achieved record-high sales and operating profit for the quarter, driven by increased sales of new, high-profit products. In the second half of the year, we plan to continue our company-wide efforts for growth, as we have a number of favorable factors such as the launch of high-margin new products and market expansion targeting major global markets including Europe and the United States."

This content was produced with the assistance of AI translation services.